- Home
- MIRM
as 07-26-2024 4:00pm EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 1.7B | IPO Year: | 2019 |
| Target Price: | $53.54 | AVG Volume (30 days): | 745.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $41.88 | Next Earning Date: | 08-05-2024 |
| Revenue: | $223,998,000 | Revenue Growth: | 133.90% |
| Revenue Growth (this year): | 72.94% | Revenue Growth (next year): | 28.40% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jul 1 '24 | Sell | $34.00 | 375 | $12,750.00 | 2,426 | SEC Form 4 |
| Vig Pamela | MIRM | CHIEF SCIENTIFIC OFFICER | Jun 24 '24 | Sell | $34.00 | 30,559 | $1,039,006.00 | 27,406 | SEC Form 4 |
| Ramasastry Saira | MIRM | Director | Jun 5 '24 | Sell | $25.68 | 5,000 | $128,400.00 | 0 | SEC Form 4 |
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Mar 27 '24 | Buy | $24.80 | 2,000 | $49,600.00 | 14,000 | SEC Form 4 |
| Radovich Peter | MIRM | PRESIDENT AND COO | Mar 25 '24 | Sell | $25.80 | 4,303 | $111,017.40 | 29,013 | SEC Form 4 |
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Mar 18 '24 | Buy | $25.80 | 2,000 | $51,600.00 | 12,000 | SEC Form 4 |
| Vig Pamela | MIRM | CHIEF SCIENTIFIC OFFICER | Feb 2 '24 | Sell | $26.19 | 1,214 | $31,796.85 | 28,691 | SEC Form 4 |
| Radovich Peter | MIRM | PRESIDENT AND COO | Feb 2 '24 | Sell | $26.19 | 1,790 | $46,883.14 | 34,695 | SEC Form 4 |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Feb 2 '24 | Sell | $26.19 | 6,013 | $157,491.29 | 104,112 | SEC Form 4 |
| Longpre Lara | MIRM | CHIEF DEVELOPMENT OFFICER | Feb 2 '24 | Sell | $26.19 | 847 | $22,184.45 | 104,407 | SEC Form 4 |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 31 '24 | Sell | $26.19 | 735 | $19,250.97 | 1,759 | SEC Form 4 |
| Peetz Christopher | MIRM | PRESIDENT AND CEO | Jan 8 '24 | Sell | $28.03 | 5,209 | $146,033.27 | 110,125 | SEC Form 4 |
| Vig Pamela | MIRM | HEAD OF RESEARCH & DEVELOPMENT | Jan 8 '24 | Sell | $28.03 | 1,408 | $39,472.29 | 29,905 | SEC Form 4 |
| Radovich Peter | MIRM | CHIEF OPERATING OFFICER | Jan 8 '24 | Sell | $28.03 | 1,408 | $39,472.58 | 36,485 | SEC Form 4 |
| Longpre Lara | MIRM | CHIEF DEVELOPMENT OFFICER | Jan 8 '24 | Sell | $28.04 | 1,019 | $28,567.67 | 105,254 | SEC Form 4 |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 6 '24 | Sell | $28.04 | 528 | $14,802.53 | 722 | SEC Form 4 |
| Howe Jolanda | MIRM | SVP, Global Controller | Dec 5 '23 | Sell | $32.40 | 2,500 | $81,000.00 | 0 | SEC Form 4 |
| Heron Patrick J | MIRM | Director | Nov 9 '23 | Buy | $28.30 | 2,910 | $82,353.00 | 161,963 | SEC Form 4 |
| Vig Pamela | MIRM | CHIEF SCIENTIFIC OFFICER | Jan 9 '23 | Sell | $20.62 | 1,379 | $28,438.15 | 27,312 | SEC Form 4 |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Jan 9 '23 | Sell | $20.62 | 5,159 | $106,390.45 | 91,953 | SEC Form 4 |
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 9 '23 | Sell | $20.62 | 1,379 | $28,438.15 | 33,316 | SEC Form 4 |
| Longpre Lara | MIRM | CHIEF DEVELOPMENT OFFICER | Sep 10 '19 | Buy | $10.64 | 965 | $10,267.60 | 105,372 | SEC Form 4 |
| Longpre Lara | MIRM | CHIEF DEVELOPMENT OFFICER | Sep 10 '19 | Sell | $20.62 | 1,003 | $20,684.17 | 104,369 | SEC Form 4 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Mirum Pharmaceuticals Gets FDA Label Expansion Approval for Liver Disease Treatment; Shares Jump
Business Wire
a day ago
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Simply Wall St.
14 days ago
Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone
Investor's Business Daily
14 days ago
Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves
Business Wire
16 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
17 days ago
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Zacks
18 days ago
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
MT Newswires
18 days ago
Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.